ACVR1 R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A

A new logic for DNA engineering using recombination in Escherichia coli

Zhang, Y., Buchholz, F., Muyrers, J. P. P., & Stewart, A. F. (1998) · Nature Genetics · doi:10.1038/2417 · Cited by 1,228

A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva

Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D., Cho, T., Choi, I. H., Connor, J. M., Delai, P. L. R., Glaser, D. L., Merrer, M. F. L., et al. (2006) · Nature Genetics · doi:10.1038/ng1783 · Cited by 1,215

GS domain mutations that constitutively activate T beta R‐I, the downstream signaling component in the TGF‐beta receptor complex.

Wieser, R., Wrana, J. L., & Massagué, J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07214.x · Cited by 689

BMP type I receptor inhibition reduces heterotopic ossification

Yu, P. B., Deng, D. Y., Lai, C. S. C., Hong, C. C., Cuny, G. D., Bouxsein, M., Hong, D. W., McManus, P. M., Katagiri, T., Sachidanandan, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1888 · Cited by 641

Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors

Attisano, L. (1993) · Cell · doi:10.1016/0092-8674(93)90488-c · Cited by 639

High-throughput engineering of the mouse genome coupled with high-resolution expression analysis

Valenzuela, D. M., Murphy, A. J., Frendewey, D. A., Gale, N. W., Economides, A. N., Auerbach, W., Poueymirou, W. T., Adams, N. C., Rojas, J., Yasenchak, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt822 · Cited by 583

Specific Activation of Smad1 Signaling Pathways by the BMP7 Type I Receptor, ALK2

Macías‐Silva, M., Hoodless, P. A., Tang, S. J., Buchwald, M., & Wrana, J. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25628 · Cited by 476

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

Murphy, A. J., Macdonald, L. E., Stevens, S. G., Karow, M. L., Dore, A. T., Pobursky, K. J., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 469

A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse

Schnütgen, F., Doerflinger, N., Calleja, C., Wendling, O., Chambon, P., & Ghyselinck, N. B. (2003) · Nature Biotechnology · doi:10.1038/nbt811 · Cited by 401

Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes

Macdonald, L. E., Karow, M. L., Stevens, S. G., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D. A., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 396

ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva

Pang, J., Zuo, Y., Chen, Y., Song, L., Zhu, Q. R., Yu, J., Shan, C., Cai, Z., Hao, J., Kaplan, F. S., et al. (2016) · Bone · doi:10.1016/j.bone.2016.07.023 · Cited by 16

Enhancer hijacking at the ARHGAP36 locus is associated with connective tissue to bone transformation

Melo, U. S., Jatzlau, J., Prada‐Medina, C. A., Flex, E., Hartmann, S., Ali, S., Schöpflin, R., Bernardini, L., Ciolfi, A., Moeinzadeh, M.-H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37585-8 · Cited by 15

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva

Srinivasan, D., Arostegui, M., Goebel, E. J., Hart, K. N., Aykul, S., Lees‐Shepard, J. B., Idone, V. J., Hatsell, S. J., & Economides, A. N. (2024) · Biomolecules · doi:10.3390/biom14010101 · Cited by 17

Activin receptors in human cancer: Functions, mechanisms, and potential clinical applications

Du, R., Wen, L., Niu, M., Zhao, L., Guan, X., Jiao, Y., Zhang, C., & Liu, H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116061 · Cited by 17

Palovarotene (Sohonos), a synthetic retinoid for reducing new heterotopic ossification in fibrodysplasia ossificans progressiva: history, present, and future

Hsiao, E. C., & Pacifici, M. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae147 · Cited by 15

Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets

Li, J., Dang, Y.-M., Liu, M., Gao, L., & Lin, H. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.102297 · Cited by 15

The effect of Activin‐A on periodontal ligament fibroblasts‐mediated osteoclast formation in healthy donors and in patients with fibrodysplasia ossificans progressiva

Schoenmaker, T., Wouters, F., Micha, D., Forouzanfar, T., Netelenbos, J. C., Eekhoff, E. M. W., Bravenboer, N., & de Vries, T. J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27693 · Cited by 15

ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma

Sekimata, K., Sato, T., & Sakai, N. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00882 · Cited by 15

Clearance of Senescent Cells From Injured Muscle Abrogates Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva

Wang, H., Zhang, Q., Kaplan, F. S., & Pignolo, R. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4458 · Cited by 16

Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles

Eekhoff, E. M. W., de Ruiter, R. D., Smilde, B. J., Schoenmaker, T., de Vries, T. J., Netelenbos, J. C., Hsiao, E. C., Scott, C., Haga, N., Grunwald, Z., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.023 · Cited by 15

A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling

Soomro, A., Khajehei, M., Li, R., O'Neil, K. S., Zhang, D., Gao, B., MacDonald, M. E., Kakoki, M., & Krepinsky, J. C. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00424-1 · Cited by 15

Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice

Lounev, V. Y., Groppe, J. C., Brewer, N. S., Wentworth, K. L., Smith, V., Xu, M., Schomburg, L., Bhargava, P., Mukaddam, M. A., Hsiao, E. C., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae029 · Cited by 16

Lymphatic Contribution to the Cellular Niche in Heterotopic Ossification

Loder, S. J., Agarwal, S., Sorkin, M., Breuler, C., Li, J., Peterson, J. M., Gardenier, J. C., Hsieh, H. H. S., Wang, S. C., Mehrara, B. J., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001619 · Cited by 15

Fibrodysplasia (Myositis) Ossificans Progressiva

Convente, M. R., Towler, O. W., Stanley, A. K., Brewer, N. S., Allen, R. S., Kaplan, F. S., & Shore, E. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00030-7 · Cited by 15

The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator

Lin, H., Shi, F., Gao, J., & Hua, P. (2019) · Bioscience Reports · doi:10.1042/bsr20190377 · Cited by 15

Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

Smilde, B. J., Stockklausner, C., Keen, R. W., Whittaker, A., Bullock, A. N., von Delft, A., van Schoor, N. M., Yu, P. B., & Eekhoff, E. M. W. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05471-x · Cited by 14

Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva

Pignolo, R. J., Mukaddam, M. A., Baujat, G., Brown, M. A., Cunto, C. L. D., Hsiao, E. C., Keen, R. W., Sang, K. L. Q., Grogan, D. R., Marino, R., et al. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-02080-7 · Cited by 14

Immunologic Aspects in Fibrodysplasia Ossificans Progressiva

Diolintzi, A., Pervin, M. S., & Hsiao, E. C. (2024) · Biomolecules · doi:10.3390/biom14030357 · Cited by 15

M-Ras is Muscle-Ras, Moderate-Ras, Mineral-Ras, Migration-Ras, and Many More-Ras

Endo, T. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112342 · Cited by 14

Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva

Khan, F., Yu, X., & Hsiao, E. C. (2021) · Biomedicines · doi:10.3390/biomedicines9020155 · Cited by 14

Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification

Yamamoto, M., Stoessel, S. J., Yamamoto, S., & Goldhamer, D. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4617 · Cited by 14

FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells

Quist-Løkken, I., Andersson-Rusch, C., Kastnes, M. H., Kolos, J., Jatzlau, J., Hella, H., Olsen, O. E., Sundan, A., Knaus, P. I., Hausch, F., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-022-01033-9 · Cited by 15

Peripheral Blood Mononuclear Cell Immunophenotyping in Fibrodysplasia Ossificans Progressiva Patients: Evidence for Monocyte DNAM1 Up‐regulation

Zotto, G. D., Antonini, F., Azzari, I., Ortolani, C., Tripodi, G., Giacopelli, F., Cappato, S., Moretta, L., Ravazzolo, R., & Bocciardi, R. (2017) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21594 · Cited by 14

Functional characterization of a unique mutant of ALK2, p.K400E, that is associated with a skeletal disorder, diffuse idiopathic skeletal hyperostosis

Tsukamoto, S., Kuratani, M., & Katagiri, T. (2020) · Bone · doi:10.1016/j.bone.2020.115410 · Cited by 14

Coordinating Tissue Regeneration Through Transforming Growth Factor-β Activated Kinase 1 Inactivation and Reactivation

Hsieh, H. H. S., Agarwal, S., Cholok, D. J., Loder, S. J., Kaneko, K., Huber, A. K., Chung, M. T., Ranganathan, K., Habbouche, J. A., Li, J., et al. (2019) · Stem Cells · doi:10.1002/stem.2991 · Cited by 13

Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva

Kaplan, F. S., Teachey, D. T., Andolina, J. R., Siegel, D. M., Mancilla, E. E., Hsiao, E. C., Mukaddam, M. A., Rocke, D. M., & Pignolo, R. J. (2021) · Bone · doi:10.1016/j.bone.2021.116016 · Cited by 13

Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1 R206H Transcript and Inhibit Osteogenic Differentiation

Maruyama, R., Nguyen, Q., Roshmi, R. R., Touznik, A., & Yokota, T. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0009 · Cited by 13

TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva

de Ruiter, R. D., Wisse, L. E., Schoenmaker, T., Yaqub, M. M., Sánchez‐Duffhues, G., Eekhoff, E. M. W., & Micha, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032299 · Cited by 13

Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification

Lu, G., Tandang‐Silvas, M. R., Dawson, A., Dawson, T. J., & Groppe, J. C. (2018) · Bone · doi:10.1016/j.bone.2018.03.027 · Cited by 14

Human iPSCs as Model Systems for BMP-Related Rare Diseases

Sánchez‐Duffhues, G., & Hiepen, C. (2023) · Cells · doi:10.3390/cells12172200 · Cited by 12

Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva

Ullrich, T., Arista, L., Weiler, S., Teixeira‐Fouchard, S., Broennimann, V., Stiefl, N., Head, V., Krämer, I., & Guth, S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128667 · Cited by 12

Beneficial Effects of Moderate Hepatic Activin A Expression on Metabolic Pathways, Inflammation, and Atherosclerosis

Liu, H., Hastings, M. H., Kitchen, R. R., Xiao, C., Guerra, J. R. B., Kuznetsov, A., & Rosenzweig, A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318138 · Cited by 12

Diminished vasculogenesis under inflammatory conditions is mediated by Activin A

Manohar‐Sindhu, S., Merfeld‐Clauss, S., Goddard, Y., March, K. L., & Traktuev, D. O. (2023) · Angiogenesis · doi:10.1007/s10456-023-09873-w · Cited by 12

A Door Opens for Fibrodysplasia Ossificans Progressiva

Katagiri, T. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.11.010 · Cited by 12

Discovery of Heterotopic Bone-Inducing Activity in Hard Tissues and the TGF-β Superfamily

Katagiri, T., Tsukamoto, S., Nakachi, Y., & Kuratani, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113586 · Cited by 12

Activation of Gq signaling by Pasteurella multocida toxin inhibits the osteoblastogenic-like actions of Activin A in C2C12 myoblasts, a cell model of fibrodysplasia ossificans progressiva

Ebner, J. K., König, G. M., Kostenis, E., Siegert, P., Aktories, K., & Orth, J. H. C. (2019) · Bone · doi:10.1016/j.bone.2019.07.031 · Cited by 12

Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva

Peng, K., Karunakaran, K. D., Labadie, R. F., Veliu, M., Cheung, C., Lee, A. M., Yu, P. B., & Upadhyay, J. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01709-4 · Cited by 12

Actions from head to toe: An update on Bone/Body Morphogenetic Proteins in health and disease

Hiepen, C., Yadin, D., Rikeit, P., Dörpholz, G., & Knaus, P. I. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.12.006 · Cited by 12

RNA Sequencing Evidences the Prevention of Oxidative Stress is Effective in Injury-Induced Heterotopic Ossification Treatment

Xie, K., Chen, L., & Yang, J. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3019 · Cited by 11

Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs

Maekawa, H., Jin, Y., Nishio, M., Kawai, S., Nagata, S., Kamakura, T., Yoshitomi, H., Niwa, A., Saito, M. K., Matsuda, S., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02506-3 · Cited by 11

Activin-A Induces Early Differential Gene Expression Exclusively in Periodontal Ligament Fibroblasts from Fibrodysplasia Ossificans Progressiva Patients

Schoenmaker, T., Mokrý, M., Micha, D., Netelenbos, J. C., Bravenboer, N., Gilijamse, M., Eekhoff, E. M. W., & de Vries, T. J. (2021) · Biomedicines · doi:10.3390/biomedicines9060629 · Cited by 11

Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva

Sun, L., Jin, Y., Nishio, M., Watanabe, M., Kamakura, T., Nagata, S., Fukuda, M., Maekawa, H., Kawai, S., Yamamoto, T., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302219 · Cited by 11

Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva

Haviv, R., Zeitlin, L., Moshe, V., Ziv, A., Rabinowicz, N., Benedetti, F. D., Prencipe, G., Matteo, V., Cunto, C. L. D., Hsiao, E. C., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae255 · Cited by 12

Interleukin-1β Suppresses the Transporter Genes Ank and Ent1 Expression in Stromal Progenitor Cells Retaining Mineralization

Ezura, Y., Lin, X., Hatta, A., Izu, Y., & Noda, M. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0139-1 · Cited by 11

Genomic Context and Mechanisms of the ACVR1 Mutation in Fibrodysplasia Ossificans Progressiva

Ravazzolo, R., & Bocciardi, R. (2021) · Biomedicines · doi:10.3390/biomedicines9020154 · Cited by 11

Association analysis of polymorphisms rs12997 in ACVR1 and rs1043784 in BMP6 genes involved in bone morphogenic protein signaling pathway in primary angle-closure and pseudoexfoliation glaucoma patients of Saudi origin

Kondkar, A. A., Sultan, T., Azad, T. A., Osman, E. A., Almobarak, F. A., & Al‐Obeidan, S. A. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01076-0 · Cited by 11

Medical guidelines for fibrodysplasia ossificans progressiva

Kaplan, F. S., Mukaddam, M. A., Baujat, G., Hidalgo‐Bravo, A., Brown, M. A., Cali, A., Cho, T., Crowe, C., Cunto, C. L. D., Delai, P. L. R., et al. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf150 · Cited by 10

Hedgehog Signaling Controls Chondrogenesis and Ectopic Bone Formation via the Yap-Ihh Axis

Cong, Q., & Yang, Y. (2024) · Biomolecules · doi:10.3390/biom14030347 · Cited by 10

Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva

Rajapakse, C. S., Lindborg, C. M., Wang, H., Newman, B. T., Kobe, E. A., Chang, G. A., Shore, E. M., Kaplan, F. S., & Pignolo, R. J. (2016) · Academic Radiology · doi:10.1016/j.acra.2016.10.010 · Cited by 10

When Limb Surgery Has Become the Only Life-Saving Therapy in FOP: A Case Report and Systematic Review of the Literature

Botman, E., Treurniet, S., Lubbers, W. D., Schwarte, L. A., Schober, P. R., Sabelis, L. W. E., Peters, E. J. G., van Schie, A., de Vries, R., Grunwald, Z., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00570 · Cited by 10

Effect of immunosuppressants on a mouse model of osteogenesis imperfecta type V harboring a heterozygous Ifitm5 c.-14C > T mutation

Hanagata, N., Takemura, T., Kamimura, K., & Koda, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78403-1 · Cited by 10

Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva

Chakkalakal, S. A., & Shore, E. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8904-1_18 · Cited by 10

Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial

Keen, R. W., Dahir, K. M., McGinniss, J., Sanchez, R. J., Mellis, S. J., Economides, A. N., Rocco, M. D., Orcel, P., Roux, C., Tabarkiewicz, J., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae140 · Cited by 9

Disorders of Mineral Metabolism II. Abnormalities of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent

Root, A. W., & Levine, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00020-8 · Cited by 9

Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography

Farid, A., Golden, E., Robicheau, S., Hu, A., Cheung, K., Yu, P. B., Rutkove, S. B., & Upadhyay, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-25610-7 · Cited by 9

Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A‐Expressing Cell Populations

Mundy, C., Yao, L., Shaughnessy, K. A., Saunders, C., Shore, E. M., Koyama, E., & Pacifici, M. (2023) · JBMR Plus · doi:10.1002/jbm4.10821 · Cited by 9

MyD88 Is Not Required for Muscle Injury-Induced Endochondral Heterotopic Ossification in a Mouse Model of Fibrodysplasia Ossificans Progressiva

Lyu, H., Elkins, C. M., Pierce, J. L., Serezani, C. H., & Perrien, D. S. (2021) · Biomedicines · doi:10.3390/biomedicines9060630 · Cited by 9

A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of theACVR1gene

Cappato, S., Traberg, R., Gintautienė, J., Zara, F., & Bocciardi, R. (2021) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1774 · Cited by 9

Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling

Xie, C., Jiang, W., Lacroix, J. J., Luo, Y., & Hao, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186498 · Cited by 9

Injury of Adult Zebrafish Expressing Acvr1l Q204D Does Not Result in Heterotopic Ossification

LaBonty, M., Pray, N., & Yelick, P. C. (2018) · Zebrafish · doi:10.1089/zeb.2018.1611 · Cited by 9

Towards a cure for Fibrodysplasia ossificans progressiva

Sánchez‐Duffhues, G., de Gorter, D. J. J., & ten Dijke, P. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.10.62 · Cited by 9

BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomasPreprint

Huchedé, P., Meyer, S., Berthelot, C., Hamadou, M., Bertrand‐Chapel, A., Rakotomalala, A., Manceau, L., Tomine, J., Lespinasse, N., Lewandowski, P., et al. (2023) · eLife · doi:10.7554/elife.91313.3 · Cited by 9

When Bone Forms Where It Shouldn’t: Heterotopic Ossification in Muscle Injury and Disease

Facchin, A., Lemaire, S., Toner, L. G., Argaw, A., & Frenette, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157516 · Cited by 9

A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders

Katagiri, T., Tsukamoto, S., Kuratani, M., Tsuji, S., Nakamura, K., Ohte, S., Kawaguchi, Y., & Takaishi, K. (2023) · Nature Communications · doi:10.1038/s41467-023-38746-5 · Cited by 8

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

Gao, P., Inada, Y., Hotta, A., Sakurai, H., & Ikeya, M. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03691-7 · Cited by 8

Tailored Teaching for Specialized (Para-)medical Students - Experience From Incorporating a Relevant Genetic Disease Throughout a Course of Molecular Cell Biology

Schoenmaker, T., Deng, D., & de Vries, T. J. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00224 · Cited by 8

Modeling the ACVR1R206H mutation in human skeletal muscle stem cells

Barruet, E., Garcia, S. M., Wu, J., Morales, B. M., Tamaki, S., Moody, T., Pomerantz, J. H., & Hsiao, E. C. (2021) · eLife · doi:10.7554/elife.66107 · Cited by 8

Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1R206H-Specific Human Cellular and Zebrafish Models

Wentworth, K. L., Lalonde, R. L., Groppe, J. C., Brewer, N. S., Moody, T. A., Hansberry, S., Taylor, K. E., Shore, E. M., Kaplan, F. S., Pignolo, R. J., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4711 · Cited by 8

Drosophila models of FOP provide mechanistic insight

Le, V. Q., Anderson, E. N., Akiyama, T., & Wharton, K. A. (2017) · Bone · doi:10.1016/j.bone.2017.11.001 · Cited by 8

Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Padilha, E. C., Wang, J., Kerns, E., Lee, A. M., Huang, W., Jiang, J., McKew, J. C., Mutlib, A. E., Peccinini, R. G., Yu, P. B., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00234 · Cited by 8

Methods for the reliable induction of heterotopic ossification in the conditional Alk2Q207D mouse.

Pan, H., Fleming, N., Hong, C. C., Mishina, Y. M., & Perrien, D. S. (2020) · Europe PMC (PubMed Central) · Cited by 8

Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology

Jimmidi, R., Monsivais, D., Ta, H. M., Sharma, K. L., Bohren, K. M., Chamakuri, S., Liao, Z., Li, F., Hakenjos, J. M., Li, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413108121 · Cited by 7

Limb specific Acvr1‐knockout during embryogenesis in mice exhibits great toe malformation as seen in Fibrodysplasia Ossificans Progressiva (FOP)

Hildebrand, L., Kegler, M. S., Walther, M., Seemann, P., & Stange, K. (2019) · Developmental Dynamics · doi:10.1002/dvdy.24 · Cited by 7

Improving the Diagnosis of Fibrodysplasia Ossificans Progressiva

Kannus, P., & Levy, C. E. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.02.036 · Cited by 7

Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva

Kou, S., Kile, S., Kambampati, S., Brady, E. C., Wallace, H., Sousa, C. M. D., Cheung, K., Dickey, L., Wentworth, K. L., & Hsiao, E. C. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02246-4 · Cited by 7

The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva

Ye, Z., Wang, S., Shan, C., Zhu, Q. R., Xue, Y., & Zhang, K. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02708-3 · Cited by 7

Cell Senescence in Heterotopic Ossification

Pignolo, R. J., Kaplan, F. S., & Wang, H. (2024) · Biomolecules · doi:10.3390/biom14040485 · Cited by 7

Do Interactions of Vitamin D3 and BMP Signaling Hold Implications in the Pathogenesis of Fibrodysplasia Ossificans Progressiva?

Pierce, J. L., & Perrien, D. S. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00673-z · Cited by 7

Axial spondyloarthritis: emerging drug targets

Cherqaoui, B., Araujo, L. M. M., Glatigny, S., & Bréban, M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1973429 · Cited by 7

An ACVR1R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva

Kaplan, F. S., Groppe, J. C., Xu, M., Towler, O. W., Grunvald, E. L., KALUNIAN, K. C., Kallish, S., Mukaddam, M. A., Pignolo, R. J., & Shore, E. M. (2021) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62585 · Cited by 7

Lymphocytes Are Not Required for Neurogenic Heterotopic Ossification Development after Spinal Cord Injury

Alexander, K. A., Tseng, H., Kulina, I., Fleming, W., Vaquette, C., Genêt, F., Ruitenberg, M. J., & Lévesque, J.-P. (2022) · Neurotrauma Reports · doi:10.1089/neur.2021.0072 · Cited by 7

Distinct Gene Expression Patterns Defining Human Osteoblasts' Response to BMP2 Treatment: Is the Therapeutic Success All a Matter of Timing?

Ehnert, S., Aspera-Werz, R. H., Freude, T., Reumann, M. K., Ochs, B. G., Bahrs, C., Schröter, S., Wintermeyer, E., Nussler, A. K., & Pscherer, S. (2016) · European Surgical Research · doi:10.1159/000447089 · Cited by 7

An Adult Zebrafish Model of Fibrodysplasia Ossificans Progressiva

LaBonty, M., & Yelick, P. C. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8904-1_11 · Cited by 7

Activin-A Induces Fewer, but Larger Osteoclasts From Monocytes in Both Healthy Controls and Fibrodysplasia Ossificans Progressiva Patients

Schoenmaker, T., Botman, E., Sariyildiz, M., Micha, D., Netelenbos, J. C., Bravenboer, N., Kelder, A., Eekhoff, E. M. W., & de Vries, T. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00501 · Cited by 9

Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish

Allen, R. S., Jones, W. D., Hale, M., Warder, B. N., Shore, E. M., & Mullins, M. C. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4869 · Cited by 6

Cellular Contributors to Bone Homeostasis

Rauner, M., Jähn, K., Hemmatian, H., Colditz, J., & Goettsch, C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-46725-8_16 · Cited by 6

Acetabular Reaming Is a Reliable Model to Produce and Characterize Periarticular Heterotopic Ossification of the Hip

Negri, S., Wang, Y., Li, Z., Qin, Q., Lee, S., Cherief, M., Xu, J., Hsu, G. C., Tower, R. J., Presson, B., et al. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac042 · Cited by 6

Polypeptide Substrate Accessibility Hypothesis: Gain-of-Function R206H Mutation Allosterically Affects Activin Receptor-like Protein Kinase Activity

Groppe, J. C., Lu, G., Tandang‐Silvas, M. R., Pathi, A., Konda, S., Wu, J., Le, V. Q., Culbert, A. L., Shore, E. M., Wharton, K. A., et al. (2023) · Biomolecules · doi:10.3390/biom13071129 · Cited by 6

A functional interplay between the two BMP-SMAD pathway inhibitors TMPRSS6 and FKBP12 regulates hepcidin expression in vivo

Pettinato, M., Aghajan, M., Guo, S., Volpe, L. B., Carleo, R., Nai, A., Pagani, A., Altamura, S., & Silvestri, L. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00305.2023 · Cited by 6

Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva

Maruyama, R., & Yokota, T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8651-4_32 · Cited by 6

Targeting heterotopic ossification by inhibiting activin receptor‑like kinase 2 function (Review)

Shi, F., Gao, J., Zou, J., Ying, Y., & Lin, H. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10556 · Cited by 6

Identification and characterization of a novel heparan sulfate-binding domain in Activin A longest variants and implications for function

Yang, E., Mundy, C., Rappaport, E. F., Pacifici, M., & Billings, P. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222784 · Cited by 6

Genetics and future therapy prospects of fibrodysplasia ossificans progressiva

Rauner, M., Seefried, L., & Shore, E. M. (2019) · Medizinische Genetik · doi:10.1007/s11825-019-00279-y · Cited by 6

Transcriptomic analysis identifies novel targets for individual bone morphogenetic protein type 1 receptors in endothelial cells

Choi, W., Lee, H., Pak, B., Han, O., Kim, M., & Jin, S. (2021) · The FASEB Journal · doi:10.1096/fj.202002071r · Cited by 6

Signaling in Osteoblast Differentiation

Hayashi, M., Ono, T., & Nakashima, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11182-1 · Cited by 7

Identification of novel macrophages and bone morphogenetic protein signals causing ectopic calcification and impairing muscle regeneration

Shi, L., He, Z., Hiraga, T., Liu, Z., Yamashita, T., Iwamoto, R., Mizoguchi, T., Nakamichi, Y., Kubota, Y., Udagawa, N., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112841 · Cited by 6

Thoracic Deformity in Fibrodysplasia Ossificans Progressiva

Kaplan, F. S., Sponseller, P. D., & Pignolo, R. J. (2025) · JBJS Reviews · doi:10.2106/jbjs.rvw.25.00042 · Cited by 5

Enhanced BMP signaling in Cathepsin K-positive tendon progenitors induces heterotopic ossification

Yamaguchi, H., Li, M., Kitami, M., Swaminathan, S., Mishina, Y. M., & Komatsu, Y. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149147 · Cited by 5

The Systems Biology of Bone Morphogenetic Proteins

Sampath, K. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-47507-3_2 · Cited by 5

Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients

Wang, H., Cunto, C. L. D., Pignolo, R. J., & Kaplan, F. S. (2021) · Bone · doi:10.1016/j.bone.2021.115978 · Cited by 5

The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response

Hildebrand, L., Stange, K., Deichsel, A., Gossen, M., & Seemann, P. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.10.001 · Cited by 37

Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva

Lees‐Shepard, J. B., Yamamoto, M., Biswas, A. A., Stoessel, S. J., Nicholas, S.-A. E., Cogswell, C. A., Devarakonda, P. M., Schneider, M. J., Cummins, S. M., Legendre, N. P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02872-2 · Cited by 228

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice

Lees-Shepard, J. B., Stoessel, S. J., Chandler, J., Bouchard, K., Bento, P., Apuzzo, L. N., Devarakonda, P. M., Hunter, J. W., & Goldhamer, D. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153795 · Cited by 41

The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva

Wolken, D. M. A., Idone, V. J., Hatsell, S. J., Yu, P. B., & Economides, A. N. (2017) · Bone · doi:10.1016/j.bone.2017.06.011 · Cited by 78

Molecular Consequences of the ACVR1R206H Mutation of Fibrodysplasia Ossificans Progressiva

Song, G.-A., Kim, H., Woo, K. M., Baek, J., Kim, G.-S., Choi, J., & Ryoo, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094557 · Cited by 114